← back to search

Steven Dow

St Petersburg University · US
Area of research
Immunology · Genetics
Research interest
Research interests include Immunotherapy and Immune Responses, Veterinary Oncology Research, Virus-based gene therapy research, and Mesenchymal stem cell research.
h-index
63
citations
12,000
works
328
NIH funding
primary concept
email

Recent publications

Toll-like receptor 3-activated allogeneic umbilical cord blood-derived mesenchymal stromal cells as an adjunct for the treatment of synovial sepsis in 3 horses.
2026cited by 0position: contributordoi
Spatial transcriptomic mapping of canine osteosarcoma reveals immune microenvironment features linked to survival.
2026cited by 0position: contributordoi
Fuzzy-logic-driven predictions of multi-tissue ingrowth for rapid screening of mechanically instructive tissue-engineering scaffolds.
2026cited by 0position: contributordoi
Senescence-associated gene pathways are differentially expressed in equine aging-related osteoarthritis.
2026cited by 0position: contributordoi
Single-cell RNA sequencing reveals the cellular and molecular heterogeneity of treatment-naïve primary osteosarcoma in dogs.
2024cited by 30position: contributordoi
Characterization of the single cell landscape in normal and osteoarthritic equine joints.
2024cited by 2position: contributordoi
Correlation of fecal microbiome dysregulation to synovial transcriptome in an equine model of obesity associated osteoarthritis.
2024cited by 0position: contributordoi
Chronic adrenergic stress and generation of myeloid-derived suppressor cells: Implications for cancer immunotherapy in dogs.
2023cited by 7position: contributordoi
Antimicrobial Properties of Equine Stromal Cells and Platelets and Future Directions
Veterinary Clinics of North America: Equine Practice 2023cited by 7position: contributordoi
Nanoparticle ocular immunotherapy for herpesvirus surface eye infections evaluated in cat infection model.
2023cited by 6position: contributordoi
Data from Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses
2023cited by 0position: contributordoi
Supplementary Table from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
2023cited by 0position: contributordoi
Supplementary Table from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
2023cited by 0position: contributordoi
Supplementary Data from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
2023cited by 0position: contributordoi
Supplemental Figures/Tables S1 from Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses
2023cited by 0position: contributordoi
Supplementary Data from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
2023cited by 0position: contributordoi
Data from Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses
2023cited by 0position: contributordoi
Data from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
2023cited by 0position: contributordoi
Supplementary Figure from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
2023cited by 0position: contributordoi
Supplemental Figures/Tables S1 from Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses
2023cited by 0position: contributordoi
Supplementary Figure from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
2023cited by 0position: contributordoi
Data from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
2023cited by 0position: contributordoi
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.
2022cited by 64position: contributordoi
Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses
Cancer Research Communications 2022cited by 27position: contributordoi
Intra-articular administration of antibiotics in horses: Justifications, risks, reconsideration of use and outcomes.
2022cited by 5position: contributordoi
Toll-like receptor activation of equine mesenchymal stromal cells to enhance antibacterial activity and immunomodulatory cytokine secretion.
2021cited by 27position: contributordoi
Use of in vitro assays to identify antibiotics that are cytotoxic to normal equine chondrocytes and synovial cells.
2021cited by 14position: contributordoi
Susceptibility of canine chondrocytes and synoviocytes to antibiotic cytotoxicity in vitro.
2021cited by 6position: contributordoi
The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment
The Journal of Immunology 2019cited by 73position: lastdoi
The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment.
2019cited by 54position: contributordoi

Grants

CHS: Small: Scaffolding Data-Centered Interactions in Online Civic Discussions
NSF2009003$564,1532020–2025PIRePORTER
DIP: Collaborative Research: CRAFT: An Online Learning Platform for Scaffolding the Crowd Feedback Loop for Design Innovation Education
NSF1636727$540,3252016–2021PIRePORTER
CAREER: Advancing Collective Innovation
NSF1636946$474,8632016–2020PIRePORTER
DIP: Collaborative Research: CRAFT: An Online Learning Platform for Scaffolding the Crowd Feedback Loop for Design Innovation Education
NSF1530615$449,1252015–2016PIRePORTER
CAREER: Advancing Collective Innovation
NSF1453501$166,0662015–2016PIRePORTER
SoCS: Collaborative Research: Strategies for Crowdsourcing Complex Design Work
NSF1208382$411,8002012–2016PIRePORTER
EXP: Collaborative Research: Engaging Interdisciplinary Students in Innovation Education through Crowd-based Technology
NSF1217096$319,8002012–2016PIRePORTER
NSF East Asia Summer Institutes for US Graduate Students
NSF0711272$4,5792007–2008PIRePORTER

Frequent collaborators

· 27 papers (2019–2026)Lyndah Chow · Colorado State University21 papers (2021–2026)Daniel P. Regan · Colorado State University15 papers (2019–2023)Dylan T. Ammons · Springer Nature7 papers (2022–2026) · 7 papers (2021–2026)Amanda Guth · 6 papers (2019–2023)Laurie R. Goodrich · Colorado State University6 papers (2021–2026)Chad Frank · Colorado State University5 papers (2022–2023)Mary-Keara Boss · Elsevier Inc.5 papers (2022–2023)Stephanie McGrath · Colorado State University5 papers (2022–2023) · 5 papers (2022–2023)Aaron J. Rozental · Colorado State University5 papers (2022–2023)Angela J. Marolf · American College of Veterinary Radiology5 papers (2022–2023)Brittany MacQuiddy · Colorado State University5 papers (2022–2023)Jade Kurihara · Colorado State University5 papers (2022–2023)Rebecca Makii · Colorado State University5 papers (2022–2023)John F. Griffin · Texas A&M University5 papers (2022–2023)Gregg Griffenhagen · Elsevier, Inc.2 papers (2021–2021)Amanda Guth · Colorado State University1 papers (2019–2019)Jonathan Coy · University of Colorado Denver1 papers (2019–2019)